![Autism And Cbd: What Science Says About Hemp Therapy [FItVIfuYe3z]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/09/ced-pexels-13091435.jpg?resize=150%2C150&ssl=1 "Autism And Cbd: What Science Says About Hemp Therapy [FItVIfuYe3z] 2")
Tirzepatide vs Semaglutide: Weight & Muscle Loss Outcomes
This article reviews tirzepatide vs semaglutide weight loss clinical evidence, highlighting differences in muscle loss outcomes. Tirzepatide shows greater total weight loss but may increase lean mass depletion compared to semaglutide. Understanding these…
Comparing Clinical Evidence of GLP-1 Receptor Agonists
GLP-1 receptor agonist clinical evidence drug comparisons reveal important sex-based differences in obesity outcomes. Understanding these differences helps tailor weight management strategies. Genetic factors also influence individual responses to GLP-1…
Clinical Evidence on Dietary Fiber and GLP-1 Receptor Agonists
Dietary fiber GLP-1 receptor agonist effects are emerging as a complementary approach in metabolic health. This evidence highlights the potential role of fermentable fibers in appetite regulation. Family medicine clinicians should consider dietary fiber…
Medicinal Cannabis Doesn’t Help Anxiety, Depression, or PTSD, Huge Review Finds
A large systematic review found limited evidence for cannabis in treating mental health disorders such as anxiety, depression, and PTSD. This challenges the widespread use of medicinal cannabis for these psychiatric conditions. Clinicians should…
GLP-1 Receptor Agonist Evidence: Weight Loss & Marriage Risk
GLP-1 receptor agonist psychosocial outcomes are important for understanding the effects of weight loss on relationships. Significant weight loss can lead to shifts in self-perception and interpersonal dynamics. Clinicians should consider counseling…
Medical Cannabis for Chronic Pain: Promise, Pharmacology, and Persistent Gaps
This 2025 medical cannabis chronic pain review examines the pharmacology and clinical evidence for cannabinoids in pain management. While promising, significant gaps remain in standardized dosing and long-term safety data. The review highlights the need…
Acute and Long-Term Psychiatric Consequences of Synthetic Cannabinoids and Related Novel Psychoactive Substances: A Systematic Review
This systematic review examines psychiatric consequences synthetic cannabinoids cause, highlighting both acute and long-term effects. Synthetic cannabinoids present significant psychiatric risks distinct from natural cannabis. Understanding these…
Comparative Effectiveness, Safety, and Acceptability of Cannabis Use Disorder Treatments
This cannabis use disorder treatment research analyzes pharmacological and psychosocial interventions through a network meta-analysis. It highlights the limited evidence for medication effectiveness and supports psychosocial approaches. The study guides…
Cannabinoids in Children: Clinical Evidence Review
The cannabinoids pediatric safety evidence review covers clinical research spanning 276 studies on cannabinoid use in children. This evolving evidence base reflects growing interest and cautious interpretation due to limited long-term safety data.…
Development of a Decision Aid to Support Shared Decision-Making on Cannabis Use for Arthritis: Protocol for a Multiphase Study.
This study focuses on shared decision-making cannabis arthritis to develop a decision aid supporting patients and clinicians. Arthritis patients often seek cannabis when conventional treatments provide partial relief. The decision aid aims to facilitate…